{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:23:16Z","timestamp":1793910196051,"version":"4.8.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface marker CD3 and malignant cell markers, including B-cell maturation antigen (BCMA), FcRH5, and G protein\u2013coupled receptor GPRC5D. These bispecific antibodies so effectively deplete plasma cells (and to some extent T-cells) that patients are at increased risk of developing infections. A systematic review and meta-analysis of infections in published studies of patients with myeloma treated with bispecific antibodies was conducted to better characterize the infection risks. A\u00a0literature search used MEDLINE, EMBASE, and Cochrane to identify relevant studies between inception and February 10, 2023, including major conference presentations. Phase 1b-3 clinical trials and observational studies were included. Sixteen clinical trials comprising 1666 patients were included. Median follow-up was 7.6\u00a0months and 38% of the cohort had penta-drug refractory disease. Pooled prevalence of all-grade infections was 56%, whereas the prevalence of grade \u22653 infections was 24%. Patients who were treated with BCMA-targeted bispecifics had significantly higher rates of grade \u22653 infections than non-BCMA bispecifics (25% vs 20%). Similarly, patients treated with bispecifics in combination with other agents had significantly higher rate of all-grade infection than those receiving monotherapy (71% vs 52%). In observational studies (n\u00a0= 293), excluded from the primary analysis to ensure no overlap with patients in clinical trials, several infections classically associated with T-cell depletion were identified. This systematic review identifies BCMA-targeted bispecifics and bispecific combination therapy as having higher infection risk, requiring vigilant infection screening and prophylaxis strategies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010539","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T11:50:36Z","timestamp":1689767436000},"page":"5898-5903","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":135,"title":["Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-3592","authenticated-orcid":false,"given":"Gemma","family":"Reynolds","sequence":"first","affiliation":[{"name":"1National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"2Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-907X","authenticated-orcid":false,"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[{"name":"3Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"5NIHR UCLH Clinical Research Facility, University College London Hospitals, NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[{"name":"6Division of Myeloma, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Ng","family":"Liet Hing","sequence":"additional","affiliation":[{"name":"7Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"7Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"8Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-2666","authenticated-orcid":false,"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"3Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0213-5470","authenticated-orcid":false,"given":"Benjamin W.","family":"Teh","sequence":"additional","affiliation":[{"name":"1National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"8Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"issue":"5","key":"2023101013103859600_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"2023101013103859600_bib2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.22.02197","article-title":"Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma","volume":"41","author":"Cliff","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2023101013103859600_bib3","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2023101013103859600_bib4","first-page":"790","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"2023101013103859600_bib5","first-page":"40","article-title":"meta: an R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R\u00a0News"},{"issue":"10","key":"2023101013103859600_bib6","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"suppl 1","key":"2023101013103859600_bib7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"issue":"31","key":"2023101013103859600_bib8","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A\u00a0phase I first-in-human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023101013103859600_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-143470","article-title":"Outcome of BCMA bite (AMG420) therapy in relapse and refractory multiple myeloma (RRMM) patients","volume":"136","author":"Topp","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2023101013103859600_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2023101013103859600_bib11","doi-asserted-by":"crossref","first-page":"10140","DOI":"10.1182\/blood-2022-159969","article-title":"Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed\/refractory multiple myeloma: a phase 1\/2 first-in-human study","volume":"140","author":"Bumma","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023101013103859600_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood-2022-166494","article-title":"Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma","volume":"140","author":"Raje","year":"2022","journal-title":"Blood"},{"issue":"32","key":"2023101013103859600_bib13","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023101013103859600_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2023101013103859600_bib15","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.1182\/blood-2022-159665","article-title":"Updated interim results from a phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC\u00ae) targeting B cell maturation antigen (BCMA) for relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Abdallah","year":"2022","journal-title":"Blood"},{"issue":"suppl 16l","key":"2023101013103859600_bib16","doi-asserted-by":"crossref","first-page":"TPS8074","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8074","article-title":"MagnetisMM-5: an open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed\/ refractory multiple myeloma","volume":"40","author":"Grosicki","year":"2022","journal-title":"J Clin Oncol"},{"issue":"SUPPL 2","key":"2023101013103859600_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01.HS9.0000829556.56345.01","article-title":"Combination of subcutaneous teclistamab with daratumumab in patients with relapsed\/refractory multiple myeloma (RRMM): results from a phase 1B multicohort study","volume":"6","author":"Rodriguez-Otero","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2023101013103859600_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023101013103859600_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2023101013103859600_bib20","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 3","key":"2023101013103859600_bib21","first-page":"174","article-title":"Novel combination immunotherapy for the treatment of relapsed\/refractory multiple myeloma: updated phase 1B results for talquetamab (a GPRC5D X CD3 bispecific antibody) in combination with daratumumab","volume":"6","author":"Van De Donk","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"2023101013103859600_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"2023101013103859600_bib23","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2023101013103859600_bib24","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023101013103859600_bib25","doi-asserted-by":"crossref","first-page":"10081","DOI":"10.1182\/blood-2022-165650","article-title":"Infectious complications of B-cell maturation antigen (BCMA)-targeted therapies for relapsed\/refractory multiple myeloma","volume":"140","author":"Hoeynck","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2023101013103859600_bib26","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"2023101013103859600_bib27","doi-asserted-by":"crossref","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"issue":"14","key":"2023101013103859600_bib28","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med."},{"key":"2023101013103859600_bib29","volume-title":"Intern Med J.","author":"Teh","year":"2023"},{"issue":"suppl 1","key":"2023101013103859600_bib30","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1182\/blood-2022-163757","article-title":"Timing and nature of infections in multiple myeloma patients treated with anti-BCMA CAR-T cells","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"issue":"Suppl","key":"2023101013103859600_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.HS9.0000936248.01150.e8","article-title":"P30 single cohort results from majestec-2: teclistamab (TEC) in combination with subcutaneous daratumumab (dara) and lenalidomide (LEN) in patients with multiple myeloma (MM)","volume":"7","author":"Searle","year":"2023","journal-title":"Hemasphere"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5898\/2083561\/blooda_adv-2023-010539-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5898\/2083561\/blooda_adv-2023-010539-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T04:35:01Z","timestamp":1702787701000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/19\/5898\/496896\/Infections-following-bispecific-antibodies-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":31,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,10,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010539","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}